CAVERJECT 20 micrograms/1 ml, lyophilizate and solution for parenteral use bottle, 1 ml
Active ingredients: ALPROSTADIL
Commercialized according to BDPMDispensing in France: Prescription only
Lyophilizate and solution for parenteral usebottle, 1 mlintracaverneuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CAVERJECT 20 microgrammes/1 ml, lyophilisat et solution pour usage parentéral
- Pharmaceutical form
- lyophilisat et solution pour usage parentéral
- Route of administration
- intracaverneuse
- Presentation description
- 1 flacon(s) en verre - 1 seringue(s) préremplie(s) en verre de 1 ml avec 2 aiguille(s)
- Marketing authorisation holder
- PFIZER HOLDING FRANCE
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 29 May 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68594342CIP73396352CIP133400933963521Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ALPROSTADILlyophilisat | 20 microgrammes · un lyophilisat | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.